Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis

[Business Wire] – Pfizer Inc. announced today detailed results from OPT Compare , a Phase 3 study of tofacitinib, the first in a new class of treatment, oral Janus kinase inhibitors, the safety and efficacy of which are being investigated for the treatme more

View todays social media effects on PFE

View the latest stocks trending across Twitter. Click to view dashboard

See who Pfizer is hiring next, click here to view